期刊
PATHOLOGY & ONCOLOGY RESEARCH
卷 14, 期 1, 页码 1-8出版社
SPRINGER
DOI: 10.1007/s12253-008-9018-z
关键词
lapatinib; targeted therapy; EGFR-inhibition; HER2-inhibition; trastuzumab resistency; breast cancer
Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据